MIRA Pharmaceuticals (NASDAQ:MIRA) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of MIRA Pharmaceuticals (NASDAQ:MIRA) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

MIRA Pharmaceuticals Trading Up 2.9%

Shares of MIRA Pharmaceuticals stock opened at $1.43 on Friday. The company has a market cap of $59.89 million, a PE ratio of -0.93 and a beta of 1.72. The company has a 50 day moving average of $1.42 and a 200-day moving average of $1.40. MIRA Pharmaceuticals has a 1-year low of $0.73 and a 1-year high of $2.45.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($0.11) by ($1.07). Research analysts forecast that MIRA Pharmaceuticals will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in MIRA Pharmaceuticals during the 2nd quarter worth $26,000. Creative Planning bought a new stake in shares of MIRA Pharmaceuticals during the second quarter worth about $27,000. International Assets Investment Management LLC acquired a new position in shares of MIRA Pharmaceuticals in the second quarter valued at approximately $42,000. Two Sigma Investments LP increased its stake in shares of MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after buying an additional 25,816 shares during the period. Finally, First American Bank raised its holdings in MIRA Pharmaceuticals by 150.0% in the 3rd quarter. First American Bank now owns 50,000 shares of the company’s stock valued at $68,000 after buying an additional 30,000 shares during the last quarter. 35.16% of the stock is currently owned by institutional investors.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.